Cell-specific targeting of IL-1R1 in the brain could have major therapeutic benefit in stroke and other cerebrovascular disease by allowing more selective targeting, improving efficacy and reducing any potential side effects. Here, IL1R1 is linked to cerebrovascular disorder.